Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions

被引：157

作者：

Marks, Paul A. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, Cell Biol & Genet Program, New York, NY 10065 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS | 2010年 / 1799卷 / 10-12期

关键词：

Histone deacetylase; DNA double strand break; HDAC inhibitor; Mechanism of action; Apoptosis; Suberoylanilide hydroxamic acid; SUBEROYLANILIDE HYDROXAMIC ACID; DOUBLE-STRAND BREAKS; CANCER-CELLS; CLASS-I; HDAC INHIBITORS; LEUKEMIA-CELLS; DNA-DAMAGE; PHASE-I; EXPRESSION; ACETYLATION;

D O I：

10.1016/j.bbagrm.2010.05.008

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

There are eleven zinc dependent histone deacetylases (HDAC) in humans which have histones and many nonhistone substrates. The substrates of these enzymes include proteins that have a role in regulation of gene expression, cell proliferation, cell migration, cell death, immune pathways and angiogenesis. Inhibitors of HDACs (HDACi) have been developed which alter the structure and function of these proteins, causing molecular and cellular changes that induce transformed cell death. The HDACi are being developed as anti-cancer drugs and have therapeutic potential for many non-oncologic diseases. (C) 2010 Elsevier B.V. All rights reserved.

引用

收藏

页码：717 / 725

页数：9

相关论文

共 141 条

[1] HDAC inhibitors as anti-inflammatory agents [J].

Adcock, I. M. .

BRITISH JOURNAL OF PHARMACOLOGY, 2007, 150 (07) :829-831

[2] HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination [J].

Adimoolam, Shanthi ;

Sirisawad, Mint ;

Chen, Jun ;

Thiemann, Patti ;

Ford, James M. ;

Buggy, Joseph J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) :19482-19487

[3] Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy [J].

Andrews, Katherine T. ;

Tran, Thanh N. ;

Wheatley, Nicole C. ;

Fairlie, David P. .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (03) :292-308

[4] Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges [J].

Atadja, Peter .

CANCER LETTERS, 2009, 280 (02) :233-241

[5] Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].

Ayton, PM ;

Cleary, ML .

ONCOGENE, 2001, 20 (40) :5695-5707

[6] Isoform-specific histone deacetylase inhibitors: The next step? [J].

Balasubramanian, Sriram ;

Verner, Erik ;

Buggy, Joseph J. .

CANCER LETTERS, 2009, 280 (02) :211-221

[7] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[8] Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control [J].

Bhaskara, Srividya ;

Chyla, Brenda J. ;

Amann, Joseph M. ;

Knutson, Sarah K. ;

Cortez, David ;

Sun, Zu-Wen ;

Hiebert, Scott W. .

MOLECULAR CELL, 2008, 30 (01) :61-72

[9]

Borbone E., 2009, ONCOGENE

[10] Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer [J].

Botrugno, Oronza Antonietta ;

Santoro, Fabio ;

Minucci, Saverio .

CANCER LETTERS, 2009, 280 (02) :134-144

← 1 2 3 4 5 6 7 8 9 10 →